Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

News & Events

Breadcrumb

  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 10 June 2022

    ORYZON at EHA-2022: iadademstat 42-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML

  • 8 June 2022

    ORYZON announces FDA Orphan Drug Designation granted to iadademstat for treatment of Small Cell Lung Cancer

  • 7 June 2022

    ORYZON awarded EU Seal of Excellence and public financing of 2 M USD to develop iadademstat in Acute Myeloid Leukemia

  • 6 June 2022

    ORYZON to give updates on corporate progress in June

  • 5 May 2022

    ORYZON reports results and corporate update for quarter ended March 31, 2022

  • 3 May 2022

    ORYZON starts preclinical collaboration on Kabuki syndrome with Kennedy Krieger Institute and Johns Hopkins University

  • 29 April 2022

    ORYZON to give updates on corporate progress in May

  • 28 March 2022

    ORYZON announces appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and continues its expansion of US corporate activities

  • 25 March 2022

    ORYZON to give updates on corporate progress in March and April

  • 21 March 2022

    ORYZON announces FDA approval of IND for FRIDA, a Phase Ib trial with iadademstat in R/R AML FLT3mut+ patients

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Next page Next ›
  • Last page Last »

Email alerts

Subscribe and stay up to date with our latest news

Subscribe
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • Inside information
    • Other relevant information
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy